FILING ANALYSIS · MONDAY, NOVEMBER 16
Neumora Therapeutics, Inc. NMRA — 8-K: Results of Operations and Financial Condition
negative
Neumora Therapeutics reported a net loss of $34.4 million for the third quarter of 2026 and announced the submission of its IND for NMRA-215, but also noted that it will require substantial additional funding to continue operating, which may not be available on favorable terms. The company's cash position was $85.7 million as of September 30, 2026.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →